EUR 138.8
(-0.86%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 88.15 Million EUR | -49.4% |
2022 | 174.22 Million EUR | -54.16% |
2021 | 380.09 Million EUR | 45.9% |
2020 | 260.51 Million EUR | 23891.69% |
2019 | -1.09 Million EUR | -100.38% |
2018 | 285.15 Million EUR | -0.27% |
2017 | 285.93 Million EUR | 57.81% |
2016 | 181.18 Million EUR | -14.75% |
2015 | 212.52 Million EUR | 249.29% |
2014 | 60.84 Million EUR | -1.4% |
2013 | 61.7 Million EUR | -20.7% |
2012 | 77.81 Million EUR | 20.29% |
2011 | 64.68 Million EUR | 209.97% |
2010 | 20.86 Million EUR | -87.22% |
2009 | 163.3 Million EUR | 18145.08% |
2008 | -905 Thousand EUR | -102.29% |
2007 | 39.53 Million EUR | -91.72% |
2006 | 477.27 Million EUR | 62.42% |
2005 | 293.85 Million EUR | 137.16% |
2004 | 123.9 Million EUR | 4.92% |
2003 | 118.09 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 92.93 Million EUR | 0.0% |
2023 Q4 | -2.91 Million EUR | 0.0% |
2023 Q2 | 91.06 Million EUR | 0.0% |
2023 FY | 88.15 Million EUR | -49.4% |
2022 FY | 174.22 Million EUR | -54.16% |
2022 Q2 | 144.47 Million EUR | 0.0% |
2022 Q4 | -59.3 Million EUR | 0.0% |
2021 Q2 | 204.82 Million EUR | 0.0% |
2021 FY | 380.09 Million EUR | 45.9% |
2021 Q4 | 175.26 Million EUR | 0.0% |
2020 Q4 | 130.85 Million EUR | 0.0% |
2020 FY | 260.51 Million EUR | 23891.69% |
2020 Q2 | 129.66 Million EUR | 0.0% |
2019 FY | -1.09 Million EUR | -100.38% |
2019 Q2 | 147.16 Million EUR | 0.0% |
2019 Q4 | 44.51 Million EUR | 0.0% |
2018 FY | 285.15 Million EUR | -0.27% |
2018 Q1 | 143.4 Million EUR | 8.71% |
2018 Q4 | 87.63 Million EUR | 0.0% |
2018 Q2 | 197.51 Million EUR | 37.73% |
2017 Q2 | 154.01 Million EUR | 115.46% |
2017 FY | 285.93 Million EUR | 57.81% |
2017 Q4 | 131.91 Million EUR | 0.0% |
2017 Q1 | 71.48 Million EUR | -4.47% |
2016 FY | 181.18 Million EUR | -14.75% |
2016 Q4 | 74.83 Million EUR | 0.0% |
2016 Q2 | 106.35 Million EUR | 134.8% |
2016 Q1 | 45.29 Million EUR | -63.14% |
2015 FY | 212.52 Million EUR | 249.29% |
2015 Q3 | 53.13 Million EUR | -40.72% |
2015 Q4 | 122.89 Million EUR | 131.3% |
2015 Q2 | 89.63 Million EUR | 68.7% |
2015 Q1 | 53.13 Million EUR | 173.93% |
2014 Q4 | 19.39 Million EUR | 27.51% |
2014 FY | 60.84 Million EUR | -1.4% |
2014 Q3 | 15.21 Million EUR | -63.3% |
2014 Q1 | 15.21 Million EUR | -48.64% |
2014 Q2 | 41.44 Million EUR | 172.49% |
2013 Q2 | 14.8 Million EUR | -4.05% |
2013 Q1 | 15.42 Million EUR | 0.0% |
2013 Q4 | 29.61 Million EUR | 91.98% |
2013 Q3 | 15.42 Million EUR | 4.22% |
2013 FY | 61.7 Million EUR | -20.7% |
2012 Q1 | 19.45 Million EUR | 0.0% |
2012 FY | 77.81 Million EUR | 20.29% |
2012 Q3 | 19.45 Million EUR | 0.0% |
2012 Q4 | 15.42 Million EUR | -20.7% |
2012 Q2 | 19.45 Million EUR | 0.0% |
2011 Q3 | 16.17 Million EUR | 0.0% |
2011 FY | 64.68 Million EUR | 209.97% |
2011 Q4 | 19.45 Million EUR | 20.29% |
2011 Q2 | 16.17 Million EUR | 0.0% |
2011 Q1 | 16.17 Million EUR | 0.0% |
2010 Q4 | 16.17 Million EUR | 209.97% |
2010 Q1 | 5.21 Million EUR | 0.0% |
2010 FY | 20.86 Million EUR | -87.22% |
2010 Q3 | 5.21 Million EUR | 0.0% |
2010 Q2 | 5.21 Million EUR | 0.0% |
2009 Q4 | 5.21 Million EUR | -87.22% |
2009 Q1 | 40.82 Million EUR | 0.0% |
2009 Q2 | 40.82 Million EUR | 0.0% |
2009 FY | 163.3 Million EUR | 18145.08% |
2009 Q3 | 40.82 Million EUR | 0.0% |
2008 Q1 | -226.25 Thousand EUR | 0.0% |
2008 Q3 | -226.25 Thousand EUR | 0.0% |
2008 Q2 | -226.25 Thousand EUR | 0.0% |
2008 Q4 | 40.82 Million EUR | 18145.08% |
2008 FY | -905 Thousand EUR | -102.29% |
2007 Q2 | 9.88 Million EUR | 0.0% |
2007 Q4 | -226.25 Thousand EUR | -102.29% |
2007 Q1 | 9.88 Million EUR | 0.0% |
2007 Q3 | 9.88 Million EUR | 0.0% |
2007 FY | 39.53 Million EUR | -91.72% |
2006 Q1 | 119.31 Million EUR | 0.0% |
2006 Q2 | 119.31 Million EUR | 0.0% |
2006 Q3 | 119.31 Million EUR | 0.0% |
2006 Q4 | 9.88 Million EUR | -91.72% |
2006 FY | 477.27 Million EUR | 62.42% |
2005 FY | 293.85 Million EUR | 137.16% |
2005 Q4 | 119.31 Million EUR | 62.42% |
2005 Q3 | 73.46 Million EUR | 0.0% |
2005 Q2 | 73.46 Million EUR | 0.0% |
2005 Q1 | 73.46 Million EUR | 0.0% |
2004 Q4 | 73.46 Million EUR | 137.16% |
2004 Q2 | 30.97 Million EUR | 0.0% |
2004 Q3 | 30.97 Million EUR | 0.0% |
2004 Q1 | 30.97 Million EUR | 0.0% |
2004 FY | 123.9 Million EUR | 4.92% |
2003 Q3 | 29.52 Million EUR | 0.0% |
2003 FY | 118.09 Million EUR | 0.0% |
2003 Q2 | 29.52 Million EUR | 0.0% |
2003 Q1 | 29.52 Million EUR | 0.0% |
2003 Q4 | 30.97 Million EUR | 4.92% |
2002 Q4 | 29.52 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.51 Million EUR | 2605.721% |
ABIVAX Société Anonyme | -147.74 Million EUR | 159.666% |
Adocia SA | -21.16 Million EUR | 516.555% |
Aelis Farma SA | -5.07 Million EUR | 1835.945% |
Biophytis S.A. | -17.02 Million EUR | 617.745% |
Advicenne S.A. | -7.03 Million EUR | 1353.751% |
genOway Société anonyme | 1.56 Million EUR | -5523.416% |
IntegraGen SA | -171.39 Thousand EUR | 51530.444% |
Medesis Pharma S.A. | -3.95 Million EUR | 2326.328% |
Neovacs S.A. | -8.74 Million EUR | 1108.198% |
NFL Biosciences SA | -3.74 Million EUR | 2453.54% |
Plant Advanced Technologies SA | 79.16 Thousand EUR | -111245.687% |
Quantum Genomics Société Anonyme | -3.17 Million EUR | 2879.967% |
Sensorion SA | -22.06 Million EUR | 499.536% |
Theranexus Société Anonyme | -6.82 Million EUR | 1391.035% |
TME Pharma N.V. | -6.73 Million EUR | 1408.659% |
Valbiotis SA | -7.36 Million EUR | 1296.407% |
TheraVet SA | -1.57 Million EUR | 5712.203% |
Valerio Therapeutics Société anonyme | -20.34 Million EUR | 533.304% |
argenx SE | -272.91 Million EUR | 132.3% |
BioSenic S.A. | -28.77 Million EUR | 406.315% |
Celyad Oncology SA | -8.44 Million EUR | 1143.457% |
DBV Technologies S.A. | -67.26 Million EUR | 231.042% |
Galapagos NV | 211.69 Million EUR | 58.36% |
Genfit S.A. | -28.89 Million EUR | 405.085% |
GeNeuro SA | -14.75 Million EUR | 697.352% |
Hyloris Pharmaceuticals SA | -15.38 Million EUR | 673.155% |
Innate Pharma S.A. | -7.57 Million EUR | 1264.482% |
Inventiva S.A. | -110.42 Million EUR | 179.828% |
MaaT Pharma SA | -19.71 Million EUR | 547.083% |
MedinCell S.A. | -25.03 Million EUR | 452.07% |
Nanobiotix S.A. | -39.7 Million EUR | 322.043% |
Onward Medical N.V. | -36.18 Million EUR | 343.64% |
Oryzon Genomics S.A. | -3.35 Million EUR | 2729.071% |
OSE Immunotherapeutics SA | -23 Million EUR | 483.216% |
Oxurion NV | -18.96 Million EUR | 564.712% |
Pharming Group N.V. | -9.75 Million EUR | 1003.505% |
Poxel S.A. | -35.09 Million EUR | 351.215% |
GenSight Biologics S.A. | -26.22 Million EUR | 436.199% |
Transgene SA | -22.32 Million EUR | 494.801% |
UCB SA | 343 Million EUR | 74.3% |
Valneva SE | -101.42 Million EUR | 186.909% |
Vivoryon Therapeutics N.V. | -28.34 Million EUR | 411.027% |